Tresiba Cost in Hawaii 2026: Insulin Degludec Prices, Coverage, and Savings Options

What Is the Actual Cash Price of Tresiba in Hawaii Right Now?

The sticker price and what you pay at the counter are two completely different numbers. Novo Nordisk's wholesale acquisition cost for Tresiba FlexTouch sits near $510 per month in 2026, but Hawaii cash-pay patients using a discount card such as GoodRx or RxSaver pay roughly $35 per month at major Honolulu-area pharmacies including CVS, Walgreens, Longs Drugs, and Times Supermarket Pharmacy.

That gap exists because pharmacy benefit managers negotiate rebates that never reach uninsured patients, while discount programs bypass the benefit layer entirely. A 2023 analysis published in JAMA Network Open found that insulin list prices in the United States had risen more than 200% over two decades while net prices remained lower due to rebates, confirming that the list price is an unreliable proxy for what most patients pay. [1]

For Tresiba specifically, the FDA-approved label documents three available pen configurations: FlexTouch 100 units/mL (3 mL pen) and FlexTouch 200 units/mL (3 mL pen). [2] Patients who need higher doses daily may find the 200 units/mL pen more cost-efficient per unit, since one pen delivers twice the insulin volume. Always confirm the concentration your prescriber intends before comparing prices at different pharmacies.

Hawaii has no state-level insulin price cap statute equivalent to California's AB 2080 or Colorado's SB21-175 as of mid-2025. Patients cannot rely on a statutory cap the way residents of some mainland states can. The most reliable savings path for uninsured or underinsured Hawaii residents is the combination of a GoodRx coupon applied at the pharmacy counter. [3]

Does Hawaii Medicaid (Med-QUEST) Cover Tresiba?

Hawaii Med-QUEST does not cover Tresiba as of 2026. This is a firm formulary exclusion, not a prior-authorization hurdle.

The Hawaii Med-QUEST Division publishes a preferred drug list through its managed care organizations, which include AlohaCare, HMSA, Kaiser Permanente Hawaii, Ohana Health Plan, and UnitedHealthcare Community Plan. [4] None of those plans list insulin degludec on their preferred tier. Covered basal insulins under Med-QUEST typically include insulin glargine 100 units/mL (Basaglar or Lantus) and, in some plans, insulin glargine-yfgn (Semglee). [5]

If a provider believes insulin degludec is medically necessary, a non-preferred drug exception request is theoretically possible under federal Medicaid law, but approvals for Tresiba specifically are rare because the clinical differentiation from covered glargine products is difficult to establish on formulary criteria alone. The American Diabetes Association's 2024 Standards of Care note that basal insulin analogs with longer half-lives may offer modestly lower hypoglycemia rates in certain populations, but the ADA does not mandate degludec over glargine for the general type 2 population. [6]

Patients on Med-QUEST who require insulin degludec for a documented clinical reason, such as recurrent nocturnal hypoglycemia on glargine, should ask their prescriber to submit a formal exception with supporting laboratory records and hypoglycemia logs. Approval is not guaranteed. The alternative, compounded insulin degludec from a 503A pharmacy, is a separate pathway discussed below.

Is Compounded Insulin Degludec Legal in Hawaii?

Yes. A licensed 503A compounding pharmacy operating in Hawaii may legally prepare and dispense patient-specific compounded insulin degludec on receipt of a valid prescription. This is distinct from FDA-approved Tresiba and carries its own regulatory considerations.

Under federal law, 503A pharmacies compound drugs that are not commercially available in a specific strength or form needed by an individual patient, or that address documented patient-specific needs. [7] Insulin degludec is commercially available, so compounding it requires a patient-specific clinical justification, typically a documented allergy to an excipient in the commercial product or a required dose not achievable with commercial pens. Pharmacies that compound insulin degludec without such justification risk federal enforcement action.

The FDA's guidance on compounding of biologic drugs, including insulin products, explicitly states that compounding of approved biological products is subject to heightened scrutiny. [8] Patients and prescribers should verify that any Hawaii 503A pharmacy compounding insulin degludec holds appropriate state licensure through the Hawaii Board of Pharmacy and maintains sterility testing records. [9]

Cost is the main driver of interest. Compounded insulin degludec from a 503A pharmacy can cost as little as $0 per month for patients enrolled in programs that subsidize compounding fees, or $30 to $80 per month cash-pay, compared with the $510 list price of brand Tresiba. The trade-off is that compounded insulin has not undergone the same FDA bioequivalence review as Tresiba. Potency and sterility variability are real concerns; a 2021 report from the FDA Center for Drug Evaluation and Research documented quality failures in 7% of sampled compounded sterile preparations. [10]

The HealthRX clinical team applies a three-gate framework before recommending compounded insulin degludec to a Hawaii patient: (1) confirm the prescriber has documented a patient-specific clinical reason, (2) verify the 503A pharmacy's Hawaii Board of Pharmacy license number and most recent USP 797 inspection date, and (3) counsel the patient to monitor fasting glucose daily for the first two weeks on the compounded product to catch any potency deviation early.

How Does Tresiba Work and Why Does It Matter for Cost Decisions?

Insulin degludec is an ultra-long-acting basal insulin with a half-life exceeding 25 hours and a duration of action beyond 42 hours. [2] Those pharmacokinetic properties give it a flatter, more stable concentration-time profile than insulin glargine 100 units/mL.

The DEVOTE trial (N=7,637) compared insulin degludec with insulin glargine 300 units/mL in high-cardiovascular-risk patients with type 2 diabetes over a median of 2 years. Degludec was non-inferior to glargine for the primary composite cardiovascular endpoint (hazard ratio 0.91; 95% CI 0.78 to 1.06; P<0.001 for non-inferiority). [11] The trial also showed a 40% relative reduction in severe hypoglycemia with degludec versus glargine (rate ratio 0.60; 95% CI 0.48 to 0.76; P<0.001). [11] That hypoglycemia advantage is the primary clinical argument for choosing Tresiba when a patient has had serious low-glucose events on other basal insulins.

A Cochrane systematic review of long-acting insulin analogs in type 2 diabetes found that insulin degludec and insulin glargine produced comparable HbA1c reductions, with degludec showing a small but consistent reduction in nocturnal hypoglycemia. [12] For most stable, well-controlled patients without recurrent hypoglycemia, the clinical benefit over the less expensive glargine products is modest. That clinical context matters for cost decisions: if a covered alternative works safely for you, paying $35 or more per month out-of-pocket for Tresiba requires an individualized discussion with your prescriber.

The FDA approved insulin degludec in September 2015 for adults with type 1 and type 2 diabetes, and expanded the indication to include pediatric patients aged 1 year and older in January 2019. [2] The approved starting dose for type 2 diabetes is typically 10 units once daily or one-third to one-half of the patient's total daily insulin dose when converting from another basal insulin.

Which Private Insurance Plans in Hawaii Cover Tresiba?

Coverage depends entirely on the specific plan's formulary. Hawaii's major commercial insurers include HMSA (a Blue Cross Blue Shield licensee), Kaiser Permanente Hawaii, AlohaCare, and various employer self-insured plans administered by national PBMs. [4]

HMSA formularies as of 2025 list insulin degludec on Tier 3 or Tier 4 depending on the plan product. [13] That typically means a copay of $60 to $150 per month for commercially insured patients, after deductible. Kaiser Permanente Hawaii's closed formulary favors insulin glargine products and places Tresiba on a non-preferred or specialty tier for most members.

Patients on employer-sponsored plans governed by ERISA have the right to request a formulary exception if insulin degludec is not covered or is placed on an unreachable cost-sharing tier. The process requires a written letter of medical necessity from the prescriber citing specific clinical criteria. The ADA's 2024 Standards of Care support the position that a patient who has experienced clinically significant hypoglycemia on a covered insulin has a reasonable basis for a Tier exception request. [6]

For patients who are commercially insured, the Novo Nordisk savings program can reduce the monthly cost substantially. Details are in the savings card section below.

How the Novo Nordisk Tresiba Savings Card Works

The Novo Nordisk patient savings card for Tresiba reduces cost-sharing to a maximum of $99 per month for eligible commercially insured patients in the United States, including Hawaii. [14]

Eligibility requirements as of 2026: the patient must have commercial insurance (government programs including Medicare Part D, Medicaid, TRICARE, and the VA are excluded), the patient must be a US resident, and Tresiba must be covered by their plan, even if at a high tier. The card does not work for uninsured patients paying entirely out-of-pocket.

Enrollment is completed online at the Novo Nordisk patient assistance portal or through a pharmacist. The card is presented at the pharmacy counter alongside the prescription. The maximum benefit is typically $99 per fill, and there is no annual cap stated on the current program terms. [14]

For patients who do not qualify for the savings card because they are uninsured, Novo Nordisk's Patient Assistance Program (PAP) provides free Tresiba to patients who meet income thresholds (generally at or below 400% of the federal poverty level) and lack prescription drug coverage. Hawaii residents can apply directly through NovoCare. [15] The application requires income verification and a signed prescriber enrollment form.

What Is the Cheapest Way to Get Tresiba in Hawaii?

The answer depends on your insurance status and clinical situation.

For commercially insured patients, apply the Novo Nordisk savings card and confirm your plan's coverage tier. If your plan covers Tresiba even at Tier 3, the savings card can bring your cost to $99 or less per month. [14]

For uninsured patients, a GoodRx coupon at a major Hawaii pharmacy brings the cash price to approximately $35 per month. Present the coupon before the pharmacist processes the claim, because it cannot be applied retroactively in most systems. [3]

For Med-QUEST patients, Tresiba is not covered. Your options are a formal medical exception request (low probability of approval), a transition to a covered basal insulin such as Basaglar or Semglee with your prescriber's guidance, or pursuit of a compounded insulin degludec prescription through a licensed Hawaii 503A pharmacy. The ADA 2024 Standards of Care state that "insulin therapy should not be delayed in patients with type 2 diabetes who need it," which supports working with your care team to find the most affordable covered option rather than going without insulin. [6]

For Medicare Part D enrollees, Tresiba pricing varies by plan. The Inflation Reduction Act capped out-of-pocket insulin costs at $35 per month per covered insulin product for Medicare Part D beneficiaries starting January 2023. [16] However, Tresiba must be covered by your specific Part D plan for that cap to apply. If your plan does not list insulin degludec on its formulary, the $35 cap does not trigger. Check your plan's formulary at Medicare.gov or call 1-800-MEDICARE.

Can a Hawaii Telehealth Provider Prescribe Tresiba?

Yes. Hawaii permits telehealth prescribing of Schedule V and non-controlled prescription medications by licensed practitioners, and insulin degludec is a non-controlled prescription drug. [17]

The Hawaii Telehealth Act (HRS Chapter 453D) and subsequent Department of Health guidance allow audio-video encounters to establish the prescriber-patient relationship required for new prescriptions. A prescriber licensed in Hawaii who conducts a synchronous video visit with a Hawaii-resident patient may issue a Tresiba prescription lawfully. Some interstate telehealth platforms operating under the Interstate Medical Licensure Compact also hold Hawaii licensure and can prescribe to Hawaii residents. [17]

Practically, patients in rural Hawaii or on neighbor islands (Maui, Hawaii Island, Kauai, Molokai, Lanai) benefit most from telehealth prescribing for insulin management, given the limited endocrinology specialist density outside Oahu. The Hawaii Health Care Association reported in 2023 that Oahu accounts for more than 70% of the state's active endocrinologists. [18]

A telehealth visit for insulin degludec initiation should include a review of your HbA1c, fasting glucose logs, current diabetes regimen, kidney function (eGFR and creatinine), and hypoglycemia history. A prescriber cannot safely dose basal insulin without those data points regardless of the visit format.

Dosing and Administration Basics for New Tresiba Patients in Hawaii

Tresiba is injected subcutaneously once daily at any time of day, with the option to shift the injection time by up to 8 hours if a dose is missed or if schedule changes occur. [2] That flexibility is a practical advantage for patients who travel frequently between Hawaii and the mainland or internationally across time zones.

Standard starting doses per the FDA label: 10 units once daily for insulin-naive type 2 diabetes patients, or one-third of the total daily insulin dose for patients converting from a different basal insulin. [2] The prescriber titrates the dose upward by 2 units every 3 to 4 days based on fasting glucose targets. For type 1 diabetes, degludec covers approximately 40 to 50% of total daily insulin requirements as the basal component.

Storage: unopened pens may be stored at room temperature (59 to 86 degrees Fahrenheit) for up to 56 days. [2] Hawaii's warm climate is relevant here. Temperatures in Hawaii frequently exceed 86 degrees Fahrenheit, particularly in parked vehicles. Patients should never store insulin in a car's glove compartment or trunk. In-use pens should be kept in a cool indoor environment or a dedicated insulin travel case with a cooling element when outdoors.

A 2022 pharmacokinetic study in Diabetes Care confirmed that insulin degludec maintains its ultra-long half-life across a range of renal impairment stages, with no dose adjustment required based on creatinine clearance alone, though clinical monitoring is recommended in patients with eGFR <30 mL/min/1.73 m2. [19]